Monitoring Required for Hepatitis B Risk When Switching to Injectable Cabotegravir/Rilpivirine
People with HIV switching to injectable cabotegravir/rilpivirine require careful hepatitis B virus (HBV) screening, according to clinical data presented at HIV Glasgow 2026.
- Hepatitis B reactivation remains a rare clinical event following a switch to long-acting injectable antiretroviral therapy.
- Baseline screening for hepatitis B surface antigen and core antibodies is necessary to assess immunity and infection history.
- Vaccination status does not always guarantee protection, as breakthrough infections can occur in asymptomatic individuals.
Research presented at the conference by the European AIDS Treatment Group (EATG) indicates that while reactivation is infrequent, clinical vigilance remains essential. Cohort studies conducted in Spain and Italy found low or non-existent rates of HBV reactivation in patients transitioning to injectable regimens. These findings address concerns regarding the safety of moving away from tenofovir-based therapies, which have traditionally provided dual coverage for both HIV and HBV.
The Italian study highlighted a critical gap in protection among patients previously considered immune. Investigators identified three vaccinated individuals who acquired hepatitis B during the observation period.
These infections were entirely asymptomatic, remaining undetected until researchers performed specific diagnostic tests for hepatitis B core antibody (anti-HBc) and surface antibody (anti-HBs). This suggests that relying solely on historical vaccination records may be insufficient for patients transitioning to antiretroviral regimens that lack HBV-active agents.
Occult hepatitis B infection (OBI)—defined by the presence of replication-competent HBV DNA in the liver despite undetectable surface antigen (HBsAg)—presents a persistent clinical challenge, according to a narrative review published in Europe PMC in 2026.
The persistence of covalently closed circular DNA within hepatocytes provides the biological foundation for potential reactivation. When patients discontinue therapies containing tenofovir or lamivudine, this residual viral reservoir can pose a morbidity risk if immune control is compromised.
The absolute risk of clinically significant reactivation appears low in patients who maintain sustained HIV virological suppression and preserved CD4+ cell counts. Researchers emphasized that a risk-based approach should guide treatment simplification rather than broad restrictions. Clinicians are advised to incorporate a patient’s complete serological history and current vaccination status into the decision-making process before finalizing an antiretroviral switch.
For individuals managing complex coinfections, coordinating care with infectious disease specialists and hepatologists is necessary to monitor liver function markers. Patients should ensure their diagnostic profile includes current testing for core antibodies to identify potential occult infection before initiating long-acting injectable therapies. Regular follow-up appointments allow providers to assess whether additional monitoring or prophylactic intervention is required to prevent viral flares.
The evidence from the 2026 reviews supports a strategy of personalized monitoring rather than uniform exclusion from long-acting therapies. By integrating serological screening with routine HIV care, providers can mitigate the potential for reactivation in patients with resolved or occult HBV infection. Future clinical protocols will likely continue to prioritize these diagnostic markers to ensure the safety of long-term antiretroviral management.
Operating across the WHO Europe region, the European AIDS Treatment Group (EATG) functions as a patient-led NGO representing individuals living with or affected by HIV and related co-infections. Founded in 1992, the organization operates as a network comprising more than 140 members from 37 countries, bringing together affected communities and advocates to address treatment standards and clinical research.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.